Novel targets in non-small cell lung cancer: ROS1 and RET fusions

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Chromosomal rearrangements involving the anaplastic lymphoma kinase (ALK) gene in non-small cell lung cancer (NSCLC) have identified oncogenic fusions as therapeutic targets.
• Genetic alterations in ROS1 and RET, including chromosomal rearrangements forming chimeric fusion kinases, have been identified in NSCLC patients.
• ROS1 and RET rearrangements are typically independent of other genetic alterations like EGFR, KRAS, or ALK, suggesting they are distinct oncogenic drivers.

Purpose of the Study:

• To review the molecular biology of ROS1 and RET rearrangements in NSCLC.
• To discuss the clinical and pathological features associated with ROS1 and RET alterations.
• To summarize detection methods and therapeutic strategies targeting ROS1 and RET in NSCLC.

Main Methods:

• Review of existing literature on ROS1 and RET rearrangements in NSCLC.
• Analysis of molecular biology, clinical presentation, and diagnostic techniques.
• Examination of targeted therapy approaches for ROS1 and RET-altered NSCLC.

Main Results:

• ROS1 and RET rearrangements occur in approximately 1%-2% of NSCLC patients, detected by various genotyping techniques.
• Patients with ROS1 or RET rearrangements exhibit unique clinical and pathological characteristics.
• These genetic alterations are generally independent of other common NSCLC mutations.

Conclusions:

• ROS1 and RET rearrangements represent independent oncogenic drivers in NSCLC, offering potential therapeutic targets.
• Unique clinical and pathological features associated with these rearrangements can aid in patient identification and trial enrollment.
• Targeting ROS1 and RET fusions holds promise for genotype-directed therapies in specific NSCLC populations.